Effective Treatments for Food Allergies: What Really Works
A food allergy can turn an ordinary snack into an emergency. For people with true immune-mediated food allergies, treatment is not about “curing” the allergy overnight. It is about preventing reactions, lowering risk, and knowing exactly what to do when exposure happens.
Food Allergy Treatment: What You Need to Know
Food allergies affect roughly 8% of children and 11% of adults in the United States, and reactions can range from mild hives to life-threatening anaphylaxis. The good news: treatment options have expanded significantly in recent years.
The Foundation: Avoidance and Emergency Preparedness
The cornerstone of food allergy management remains strict avoidance of trigger foods. This means reading labels carefully, understanding cross-contamination risks, and communicating clearly at restaurants and social gatherings. In the U.S., nine foods account for over 90% of allergic reactions: milk, eggs, peanuts, tree nuts, wheat, soy, fish, shellfish, and sesame.
Every person with a diagnosed food allergy should carry injectable epinephrine and have a written emergency action plan. Epinephrine is the only first-line treatment for anaphylaxis — antihistamines alone cannot stop a severe reaction. If epinephrine is used, call 911 immediately, as symptoms can return hours later.
Oral Immunotherapy: Building Tolerance
Oral immunotherapy (OIT) represents a major advance. In OIT, patients consume tiny, gradually increasing amounts of the allergen daily under medical supervision. The goal is desensitization — raising the threshold at which an allergic reaction occurs, providing a safety net against accidental exposures.
In 2020, the FDA approved the first OIT product, Palforzia, for peanut allergy in children and teens. Clinical trials showed that most treated patients could tolerate at least two peanuts' worth of protein after treatment. OIT does carry risks, including allergic reactions during treatment, and requires ongoing daily dosing to maintain its protective effect.
Omalizumab: A New Option for Multiple Allergies
In 2024, the FDA approved omalizumab (Xolair) — an injectable biologic — to reduce the risk of allergic reactions from accidental food exposure in patients aged one year and older with one or more IgE-mediated food allergies. Unlike OIT, which targets a single allergen, omalizumab works broadly by blocking IgE, the antibody that drives allergic reactions. It is used alongside continued food avoidance, not as a replacement.
Looking Ahead
Researchers are also studying sublingual immunotherapy (drops under the tongue), skin patches that deliver allergens, and combinations of biologics with OIT to improve safety and long-term outcomes.
If you or your child has a food allergy, talk with an allergist about which treatment approach is right for your situation. The field is evolving rapidly, and more options are available today than ever before.
Comments